Lyell Immunopharma (LYEL) Research & Development (2020 - 2026)

Lyell Immunopharma has reported Research & Development for 7 years, with the latest figure at $36.6 million in Q1 2026.

• Quarterly Research & Development fell 15.75% year-over-year to $36.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $151.8 million (down 11.66% YoY) and the FY2025 annual result came in at $158.7 million, down 7.53% from the prior year.
• Research & Development retreated to $36.6 million in Q1 2026 per LYEL's latest filing, from $52.2 million in the prior quarter.
• Over five years, Research & Development peaked at $52.2 million in Q4 2025 and troughed at $28.2 million in Q3 2025.
• A 5-year average of $41.7 million and a median of $43.2 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development surged 97.21% in 2022, then slipped 28.68% in 2025.
• Over 5 years, Research & Development stood at $38.0 million in 2022, then advanced by 23.57% to $47.0 million in 2023, then advanced by 3.56% to $48.7 million in 2024, then grew by 7.26% to $52.2 million in 2025, then decreased by 29.88% to $36.6 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $36.6 million, $52.2 million, and $28.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.